Interleukin‐33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species‐mediated inhibition of nuclear factor kappa‐B signal and stemness properties

Ähnliche Einträge

• 5,7,4′‐Trimethoxyflavone triggers cancer cell PD‐L1 ubiquitin–proteasome degradation and facilitates antitumor immunity by targeting HRD1
  von: Jianhua Xia, et al.
  Veröffentlicht: (2024)
• Circulating Interleukin‐6 Predicts Adverse Outcomes in Asians with Hypertrophic Cardiomyopathy
  von: Thu‐Thao Le, et al.
  Veröffentlicht: (2025)
• Partial reduction of interleukin‐33 signaling improves senescence and renal injury in diabetic nephropathy
  von: Li Chen, et al.
  Veröffentlicht: (2024)
• Development of potent pan‐coronavirus fusion inhibitors with a new design strategy
  von: Yuanmei Zhu, et al.
  Veröffentlicht: (2024)
• Gallium complex K6 inhibits colorectal cancer by increasing ROS levels to induce DNA damage and enhance phosphatase and tensin homolog activity
  von: Wei Li, et al.
  Veröffentlicht: (2024)